Anagram Therapeutics

Focus: Anagram Therapeutics is a pre-revenue biotech company focused on inhaled glycopolymer-based therapeutics for pulmonary and systemic diseases. The company operates as a specialized player in respiratory drug delivery with a differentiated platform approach.

Respiratory

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Anagram Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Anagram Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BraiN20

Acute Stroke

N/A

STERN FIX

Sternotomy

N/A

Clinical Trials (1)

Help build intelligence for Anagram Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Join a platform-driven biotech with proprietary glycopolymer technology differentiating it in respiratory therapeutics
Early-stage opportunity to shape drug development from Phase 1/2 with direct impact on pipeline advancement
Active hiring in Analytical Sciences and Formulation Development signals near-term milestones and technical problem-solving work

Watch Out For

Only 2 active clinical programs (1 Phase 1, 1 Phase 2) creates limited career visibility and narrow product exposure
Pre-revenue status with unknown funding and employee count raises sustainability and growth trajectory uncertainty
Minimal publication output (0 recorded) suggests early stage science maturation and potentially limited external validation

Generated by Claude from Anagram Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT05784532Sternal Fixation With STERN FIX After Medial Sternotomy

N/A

Direct transfer to an Endovascular Center

Stroke

N/A

ApTOLL

Stroke

Phase 1

ApTOLL

Stroke

Phase 1/2

ANG003